Nobilis Therapeutics Enters into Collaboration with The Linde Group to Support Its Clinical Research Program to Study a drug/device combination for Treatment of PTSD and Other CNS Disorders.

PORTLAND, Ore., January 10, 2019 (Newswire.com) – ​​Nobilis Therapeutics, a biopharmaceutical company focused on the advancement of innovative Central Nervous System therapies based upon the use of noble gas mixtures, today announced that it has entered into a...

Nobilis Therapeutics just published an article “Xenon as Promising Treatment for Patients with PTSD: Case Report, Justification of Approach and Review of Literature” in Annals of Psychiatry and Mental Health.

The article begins with a fascinating case report of a patient who had suffered from PTSD for 8 years and who, after receiving the course of treatment with xenon-augmented memory reconsolidation, was reported to have a complete recovery from symptoms of this...